Acrivon Therapeutics (ACRV) Capital Expenditures (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Capital Expenditures of $14000.0 for Q1 2026, down 75.86% year-over-year from $58000.0 in Q1 2025, and down 93.61% quarter-over-quarter from $219000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Capital Expenditures (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Capital Expenditures for 6 consecutive years, with $14000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 75.86% year-over-year to $14000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 285.07% YoY), while the FY2025 annual figure was $1.7 million, up 41.56% from the prior year.
- Capital Expenditures eased to $14000.0 in Q1 2026 per ACRV's latest filing, from $219000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.2 million in Q4 2023 and bottomed at $14000.0 in Q1 2026.
- Historically, Capital Expenditures has averaged $421066.7 across 5 years, with a median of $251000.0 in 2022.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 93.98% — and 2024, when it soared 3160.0%.
- Acrivon Therapeutics' Capital Expenditures stood at $251000.0 in 2022, then jumped by 358.57% to $1.2 million in 2023, then tumbled by 80.28% to $227000.0 in 2024, then fell by 3.52% to $219000.0 in 2025, then slumped by 93.61% to $14000.0 in 2026.
- Business Quant data shows ACRV's Capital Expenditures at $14000.0 in Q1 2026, $219000.0 in Q4 2025, and $899000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | 87,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87,000.00 |
| Jun 30, 2026 | 87,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | 219,000.00 |
| Dec 31, 2025 | 219,000.00 |
| Sep 30, 2025 | 899,000.00 |
| Sep 30, 2025 | 899,000.00 |
| Jun 30, 2025 | 493,000.00 |
| Jun 30, 2025 | 493,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 137,000.00 |
| Mar 31, 2024 | 815,000.00 |
| Mar 31, 2024 | 815,000.00 |
| Dec 31, 2023 | 1.15 Mn |
| Dec 31, 2023 | 1.15 Mn |